ReviewCells2021
Experimental Models to Study COVID-19 Effect in Stem Cells.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Insights into organoid-based modeling of COVID-19 pathology.Virology journal · 2023Review
- Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy.Cancers · 2022Review
- An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models.Journal of molecular biology · 2022Review
- SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids.Cell stem cell · 2022Article
- A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.International immunopharmacology · 2021Review
- A Review on the Role of Stem Cells against SARS-CoV-2 in Children and Pregnant Women.International journal of molecular sciences · 2021Review
- Multilevel systems biology analysis of lung transcriptomics data identifies key miRNAs and potential miRNA target genes for SARS-CoV-2 infection.Computers in biology and medicine · 2021Article
- Recent Advances of COVID-19 Modeling Based on Regenerative Medicine.Frontiers in cell and developmental biology · 2021Review
- SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The new strain of coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) emerged in 2019 and hence is often referred to as coronavirus disease 2019 (COVID-19). This disease causes hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), and is considered as the cause of a global pandemic. Very limited reports in addition to ex vivo model systems are available to understand the mechanism of action of this virus, which can be used for testing of any drug efficacy against virus infectivity. COVID-19 induces tissue stem cell loss, resulting inhibition of epithelial repair followed by inflammatory fibrotic consequences. Development of clinically relevant models is important to examine the impact of the COVID-19 virus in tissue stem cells among different organs. In this review, we discuss ex vivo experimental models available to study the effect of COVID-19 on tissue stem cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.